PharmaCann Closing Pennsylvania Cannabis Facility, Laying Off 60 More Workers
PharmaCann, one of the nation’s largest privately held cannabis multistate operators (MSOs), is shuttering a major cultivation and processing facility in Pennsylvania. The move will result in the layoff of approximately 60 employees, marking the company’s latest contraction in a tightening East Coast market.
The facility, located in Holbrook, Greene County, served as a primary production hub for PharmaCann’s "Verilife" retail brand and wholesale operations within the state. According to a notice filed with state labor officials, the closure is expected to be finalized by the end of the second quarter of 2026.
A Pattern of Retrenchment
This closure follows a string of similar moves by PharmaCann and other MSOs as the industry grapples with falling wholesale prices and a lack of movement on adult-use legalization in Harrisburg.
Previous Cuts: Just six months ago, PharmaCann laid off dozens of workers at its New York production site, citing the need to "optimize the supply chain" amid a slower-than-expected rollout of retail dispensaries in that state.
Wider Industry Trend: PharmaCann is not alone; in the last year, competitors like Trulieve and Canopy Growth have also exited or scaled back operations in various regional markets to preserve capital.
Impact on the Pennsylvania Market
Pennsylvania remains a medical-only market. While the state has over 150 operating dispensaries, the lack of an adult-use "trigger" has led to a saturated wholesale environment. Operators who built massive cultivation footprints in anticipation of a 2024 or 2025 legalization date are now finding themselves with excess capacity and high overhead.
"Decisions like these are never easy, but they are necessary to ensure the long-term health of our business," a PharmaCann spokesperson said in a statement. "We remain committed to serving our Pennsylvania patients through our Verilife dispensaries, which will continue to source high-quality products from our remaining partners."
The affected employees in Holbrook were reportedly offered severance packages and the opportunity to apply for open positions at other PharmaCann locations, though most of those roles are located out of state.
